Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the medical research company's stock.

CTSO has been the topic of several other research reports. EF Hutton Acquisition Co. I upgraded shares of Cytosorbents to a "strong-buy" rating in a research note on Monday, July 29th. HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Wednesday, August 14th.

Cytosorbents Trading Down 1.0 %

NASDAQ CTSO traded down $0.01 on Friday, hitting $1.00. 104,931 shares of the stock were exchanged, compared to its average volume of 121,703. The company's 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $2.15. The company has a market capitalization of $54.43 million, a price-to-earnings ratio of -1.89 and a beta of 0.51.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $9.73 million. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Research analysts predict that Cytosorbents will post -0.31 EPS for the current year.

Institutional Trading of Cytosorbents

Large investors have recently added to or reduced their stakes in the business. CM Management LLC boosted its stake in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock worth $598,000 after acquiring an additional 25,000 shares in the last quarter. Atomi Financial Group Inc. bought a new stake in Cytosorbents during the third quarter worth approximately $51,000. Sargent Investment Group LLC grew its holdings in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock valued at $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Finally, Avenir Corp raised its position in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company's stock valued at $3,014,000 after purchasing an additional 121,294 shares during the period. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.